FDA Grants breakthrough therapy designation to Biogen’s salanersen for SMA
Biogen (NASDAQ:BIIB) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its investigational antisense oligonucleotide, salanersen, for the treatment of spinal muscular atrophy (SMA).









_1414279_640x360_2502475843727-640x360.webp&w=3840&q=75)

_1414282_640x360_2502479939617-640x360.webp&w=3840&q=75)